在非小细胞肺癌中对HER2变化的管理 - - 过去,现在和未来的经验
Jorn Nützinger1, Jii Bum Lee2, Jia Li Low1
1Department of Haematology-Oncology, National University Cancer Institute, Singapore.
Lung cancer (Amsterdam, Netherlands)
|October 9, 2023
概括
在非小细胞肺癌 (NSCLC) 中HER2突变以前的治疗结果很差. 特拉斯图祖马布德鲁克斯泰坎是一种新型抗体药物合物 (ADC),现在是对HER2突变转移性NSCLC的第一个批准治疗方法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 在非小细胞肺癌 (NSCLC) 病例中,HER2突变被发现在2-4%中.
- 从历史上看,HER2突变NSCLC对化疗和免疫疗法的反应有限.
- 与乳腺癌和胃癌不同,HER2突变性NSCLC不会对传统的HER2向药物如trastuzumab或TDM1做出反应.
研究的目的:
- 审查在NSCLC中HER2变化的生物学.
- 讨论检测HER2过度表达,放大和突变的方法.
- 总结当前的治疗环境,包括针对性治疗的临床试验.
主要方法:
- 关于HER2生物学和检测方法的文献综述.
- 对各种治疗方式的临床试验数据的分析.
- 综合关于氨酸激酶抑制剂 (TKI),抗体药物合物 (ADC) 和其他研究药物的信息.
主要成果:
- 特拉斯图祖马布德鲁克斯坦 (ADC) 是第一个也是唯一经批准的治疗HER2突变转移性NSCLC后标准治疗失败的治疗方法.
- HER2突变代表NSCLC的一个独特的分子亚型,与HER2过度表达/放大不同.
- 目前正在进行的临床试验正在探索各种向药物,包括TKI和ADC.
结论:
- HER2突变NSCLC需要特定的治疗策略,与其他由HER2驱动的癌症不同.
- 特拉斯图祖马布德鲁克斯泰坎为这种患者群体提供了一种新的,已获批准的治疗途径.
- 进一步的研究和临床试验对于推进HER2突变NSCLC的治疗选择至关重要.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.9K
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K